CRNX icon

Crinetics Pharmaceuticals

30.15 USD
-0.27
0.89%
At close Apr 21, 4:00 PM EDT
After hours
30.15
+0.00
0.00%
1 day
-0.89%
5 days
1.55%
1 month
-12.41%
3 months
-22.21%
6 months
-48.64%
Year to date
-41.51%
1 year
-30.59%
5 years
78.93%
10 years
23.01%
 

About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Employees: 437

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

159% more call options, than puts

Call options by funds: $1.7M | Put options by funds: $654K

71% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 65

68% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 22

18% more capital invested

Capital invested by funds: $4.32B [Q3] → $5.1B (+$775M) [Q4]

17% more funds holding in top 10

Funds holding in top 10: 12 [Q3] → 14 (+2) [Q4]

5% more funds holding

Funds holding: 233 [Q3] → 244 (+11) [Q4]

1.89% more ownership

Funds ownership: 105.58% [Q3] → 107.47% (+1.89%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$55
82%
upside
Avg. target
$69
128%
upside
High target
$91
202%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
Alex Thompson
43% 1-year accuracy
3 / 7 met price target
99%upside
$60
Buy
Initiated
25 Mar 2025
Citizens Capital Markets
Jonathan Wolleben
34% 1-year accuracy
23 / 67 met price target
202%upside
$91
Market Outperform
Maintained
28 Feb 2025
Jefferies
Dennis Ding
0% 1-year accuracy
0 / 5 met price target
82%upside
$55
Buy
Upgraded
22 Jan 2025

Financial journalist opinion

Based on 4 articles about CRNX published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Neutral
GlobeNewsWire
1 week ago
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and granted an aggregate of 84,725 restricted stock unit (“RSU”) awards to 26 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
2 weeks ago
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA
Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over injectable somatostatin analogs, achieving high IGF-1 control rates in pretreated patients. Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant in congenital adrenal hyperplasia highlight CRNX's expanding therapeutic potential.
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA
Neutral
GlobeNewsWire
3 weeks ago
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).   Additionally, the EMA on February 27, 2025 granted paltusotine Orphan Drug Designation (ODD) for the treatment of acromegaly.
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee; and granted an aggregate of 40,775 restricted stock unit (“RSU”) awards to sixteen new non-executive employees and 52,000 to one new executive employee; in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
1 month ago
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Steve Betz - Founder & Chief Scientific Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Tyler Van Buren - TD Cowen Joe Schwartz - Leerink Partners Jessica Fye - J.P. Morgan Gavin Clark-Gartner - Evercore ISI Catherine Okoukoni - Citizens Dennis Ding - Jefferies Catherine Novack - Jones Trading Rohan Mathur - Oppenheimer Andy Chen - Wolfe Research Charles Moore - Baird Operator Good afternoon, everyone.
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and Additional Early-Stage Trials from Development Pipeline in 2025 Strong Financial Position with $1.4B Cash with Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience.
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL.
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™